SYSMEX CORP.UNSP.ADR 1/2 Logo
US87184P1093
A12EJE
SSMXY

SYSMEX CORP.UNSP.ADR 1/2

Loading quotes...

Forecast

Buy
  0
Hold
  1
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics
In 2026, SYSMEX CORP.UNSP.ADR 1/2 has already paid €0.10 in dividends. The last payout was in July.

Financials

In the last quarter, SYSMEX CORP.UNSP.ADR 1/2 had revenue of €795.94M and net profit of €51.74M
(EUR) September 2026
YoY
Revenue 795.94M 7.16%
Gross profit 415.05M 4.05%
Net profit 51.74M 38.94%
EBITDA 201.73M 2.89%

Fundamentals

Metric Value
Market capitalization
€7.15B
Number of shares
606.88M
52-week high/low
€12.49 - €7.28
Dividend yield
1.78%
Dividends TTM
€0.21
Beta
0.69
P/E ratio
37.25
PEG ratio
-1.47
P/B ratio
2.61
P/S ratio
2.32

Company profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. Sysmex Corporation has a strategic alliance with QIAGEN N.V. for the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Name
SYSMEX CORP.UNSP.ADR 1/2
CEO
Hisashi Ietsugu
Headquarters Kobe, hy
Japan
Website
IPO
10/17/2011
Employees 10,861

Ticker symbols

Exchange Symbol
Pnk
SSMXY
Frankfurt
0YX0.F
Düsseldorf
0YX0.DU
München
0YX0.MU
🍪

Parqet  uses cookies. Learn more